IMR Press / RCM / Volume 3 / Issue 3 / pii/1561516713781-17604687

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Show Less
1 Clinical Development, Accuray, Inc., Sunnyvale, CA
2020 Division of Cardiology, University of California, San Francisco, San Francisco, CA
Rev. Cardiovasc. Med. 2002, 3(3), 138–144;
Published: 30 September 2002
Several clinical trials of therapeutic angiogenesis in patients with coronary artery disease have shown clinical improvement and provided some objective evidence of improved perfusion and left ventricular function. Larger-scale, placebo-controlled trials, as well as studies of combinations of growth factors and the use of endothelial progenitor-cell or stem-cell supplementation, are in progress. Revascularization of ischemic myocardium with angiogenic compounds and without the mechanical manipulation of atherosclerotic vessels has great potential in the treatment of coronary artery disease. If it is proven to be both safe and efficacious, the revascularization of tissue biologically via medical or gene therapy will be a major advance in the treatment of patients with a diffuse disease that is not amenable to conventional therapy and in the augmentation of revascularization in patients undergoing traditional surgical therapies.
Fibroblast growth factors
Vascular endothelial growth factor
Transforming growth factor
Gene therapy
Gene transfer
Myocardial angiogenesis
Back to top